Condition: Juvenile Psoriatic Arthritis · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Ann and Robert H Lurie Childs Hosp | Chicago, Illinois, United States | Recruiting |
| Levine Childrens Hospital | Charlotte, North Carolina, United States | Recruiting |
| Cincinnati Childrens Hospital | Cincinnati, Ohio, United States | Recruiting |
| Univ Hosp Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| Legacy Emanuel Research Hosp Portland | Portland, Oregon, United States | Recruiting |
| Childrens Hosp Pittsburgh UPMC | Pittsburgh, Pennsylvania, United States | Recruiting |
| Texas Arthritis Center | El Paso, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06751238